Foghorn Therapeutics Inc. — Investor Relations & Filings

Foghorn Therapeutics Inc. is a biopharmaceutical company pioneering a new class of medicines that target the chromatin regulatory system to treat serious diseases. The company's approach focuses on correcting abnormal gene expression, a key driver in many illnesses. The chromatin regulatory system orchestrates which genes are turned on or off by modifying the 3D structure of DNA. Foghorn develops precision therapeutic candidates designed to address genetically determined dependencies within this system. The primary therapeutic area of focus is oncology, as breakdowns in chromatin regulation are associated with more than half of all cancers. The company also explores applications for its platform in other diseases, including neurology.